Avelumab (Bavencio) for metastatic bladder cancer
Contents
Regimen in use at
- Bladder cancer (transclusion) (← links)
- Avelumab (Bavencio) in all diseases (transclusion) (← links)
Regimen
| Study | Evidence | Efficacy |
|---|---|---|
| Apolo et al. 2017 (JAVELIN) | Phase Ib (RT) | 18% (95% CI 8-33) |
Immunotherapy
- Avelumab (Bavencio) 10 mg/kg IV over 60 minutes once on day 1
Supportive medications
Per Apolo et al. 2017 (JAVELIN):
- "All patients were premedicated with an antihistamine and acetaminophen (doses and routes not given)
- The avelumab package insert suggests "Premedicate with acetaminophen and an antihistamine for the first 4 infusions and subsequently as needed."
14-day cycles
References
- Phase 1: Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, Mega AE, Britten CD, Ravaud A, Mita AC, Safran H, Stinchcombe TE, Srdanov M, Gelb AB, Schlichting M, Chin K, Gulley JL. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: Results from a multicenter, phase Ib study. J Clin Oncol. 2017 Jul 1;35(19):2117-2124. Epub 2017 Apr 4. link to original article contains verified protocol link to PMC article PubMed
